Nivolumab

Generic Name
Nivolumab
Brand Names
Opdivo, Opdualag
Drug Type
Biotech
Chemical Formula
-
CAS Number
946414-94-4
Unique Ingredient Identifier
31YO63LBSN
Background

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...

Indication

Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...

Associated Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
Complete Surgical Resection, Neoadjuvant Therapies
Clinical Trials
Related News

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

First Posted Date
2023-10-24
Last Posted Date
2024-12-13
Lead Sponsor
AstraZeneca
Target Recruit Count
600
Registration Number
NCT06097728
Locations
🇬🇧

Research Site, Taunton, United Kingdom

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

First Posted Date
2023-10-23
Last Posted Date
2024-10-14
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1
Registration Number
NCT06094296
Locations
🇺🇸

Local Institution - 0058, Boise, Idaho, United States

🇺🇸

Local Institution - 0044, Clermont, Florida, United States

🇺🇸

Local Institution - 0049, Houston, Texas, United States

and more 5 locations

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

First Posted Date
2023-10-03
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
50
Registration Number
NCT06064097
Locations
🇺🇸

Lurie Children's Hospital-Chicago, Chicago, Illinois, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 40 locations

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

First Posted Date
2023-09-28
Last Posted Date
2024-08-22
Lead Sponsor
CatalYm GmbH
Target Recruit Count
30
Registration Number
NCT06059547
Locations
🇮🇹

Istituto Nazionale Tumori IRCCS - Fondazione Pascale, Napoli, Italy

🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

🇮🇹

Istituto Oncologico Veneto, IOV - IRCCS, Padova, Italy

and more 5 locations

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Phase 2
Recruiting
Conditions
Renal Cell Carcinoma
Interventions
Drug: Tivozanib
Drug: Nivolumab
First Posted Date
2023-09-26
Last Posted Date
2024-08-27
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
48
Registration Number
NCT06053658
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Phase 3
Recruiting
Conditions
Melanoma
Interventions
Drug: ABP 206
Drug: Nivolumab
First Posted Date
2023-09-26
Last Posted Date
2024-12-18
Lead Sponsor
Amgen
Target Recruit Count
620
Registration Number
NCT06054555
Locations
🇭🇺

Pecsi Tudomanyegyetem Klinikai Kozpont, Szeged, Hungary

🇰🇷

Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of

🇹🇷

Gazi Universitesi Tip Fakultesi Hastanesi, Yenimahalle/Ankara, Ankara, Turkey

and more 142 locations

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

First Posted Date
2023-09-22
Last Posted Date
2024-12-11
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
30
Registration Number
NCT06049576
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

First Posted Date
2023-09-21
Last Posted Date
2024-10-16
Lead Sponsor
Neonc Technologies, Inc.
Target Recruit Count
134
Registration Number
NCT06047379
Locations
🇺🇸

Precision NextGen Oncology, Beverly Hills, California, United States

🇺🇸

Northwest Medical Specialties, Tacoma, Washington, United States

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

First Posted Date
2023-09-13
Last Posted Date
2024-11-01
Lead Sponsor
Molecular Templates, Inc.
Target Recruit Count
15
Registration Number
NCT06034860
Locations
🇺🇸

The Angeles Clinic, Los Angeles, California, United States

🇺🇸

Horizon Oncology Research, LLC, Lafayette, Indiana, United States

🇺🇸

Washington University in St. Louis, Saint Louis, Missouri, United States

and more 2 locations

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

First Posted Date
2023-09-11
Last Posted Date
2024-03-07
Lead Sponsor
Isala
Target Recruit Count
679
Registration Number
NCT06031233
Locations
🇳🇱

Isala Hospital, Zwolle, Netherlands

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy